PROCEPT BioRobotics Corp

PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. It manufactures and sells the AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating BPH. The firm's proprietary AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The company was founded by Nikolai Aljuri and Rodney C. Perkins in 2007 and is headquartered in Redwood City, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

PROCEPT BioRobotics Corp achieves record revenue growth, eyes market expansion

PROCEPT BioRobotics Corp demonstrated strong financial growth in Q4 2022, with revenue surging by 135% year-over-year, setting the stage for continued expansion and market success.
While facing challenges such as high operating expenses and margin pressures, the company remains focused on innovation, market diversification, and operational improvements to drive future profitability.
With a clear strategy to enhance sales efforts, expand market reach, and invest in R&D, PROCEPT BioRobotics Corp is well-positioned to capitalize on growth opportunities and solidify its presence in the medical technology sector.
Overall, the company's performance highlights a balance between revenue growth initiatives, cost management strategies, and a commitment to delivering high-quality healthcare solutions, signaling a positive outlook for future success.

PROCEPT BioRobotics Corp reports strong Q1 growth and eyes global expansion

PROCEPT BioRobotics Corp delivered strong Q1 results with robust revenue growth and margin expectations, despite profitability challenges.
The company's focus on long-term growth, pricing discipline, and market opportunities position it well for future success and becoming a standard of care for BPH.
While facing challenges like operating expenses and sales performance, PROCEPT BioRobotics remains optimistic about international expansion and market potential.
With a solid financial foundation, high surgeon retention rates, and exciting growth prospects in new markets, the company is poised for continued success.

PROCEPT BioRobotics Corp achieves record revenue and strategic partnerships

PROCEPT BioRobotics delivered a standout performance in Q2 2023, marked by record revenue, strong U.S. system sales, and international growth, supported by strategic partnerships and positive payer coverage updates.
While facing challenges from dilutive effects of new system placements and market evaluation complexities, the company's focus on innovation, financial strength, and growth opportunities position them well for future success.
By capitalizing on the momentum in system sales, expanding market reach, and leveraging the trend towards innovative treatments, PROCEPT BioRobotics is poised for continued growth and market leadership in the healthcare sector.

PROCEPT BioRobotics reports record Q3 revenue and eyes international expansion

PROCEPT BioRobotics delivered a strong quarter marked by revenue growth, improved gross margin, and strategic equity financing, positioning the company for future success.
While facing challenges in profitability and international sales, the company's focus on cost control, expansion, and innovative therapies presents avenues for growth and market leadership.
Overall, PRCT's performance reflects resilience and strategic foresight, supported by a confident management team and a clear vision for sustained growth and profitability.

PROCEPT BioRobotics Corp reports robust revenue growth and strategic focus

PROCEPT BioRobotics Corp delivered strong revenue growth in Q4 2023 and provided optimistic guidance for 2024, focusing on gross margin expansion and disciplined expense management.
The company's strategic strengths lie in innovation, customer base expansion, and patient awareness initiatives, while challenges include managing operating expenses and market dynamics.
Opportunities for PROCEPT include leveraging R&D investments, patient education, and market presentations to capture a larger share of the BPH patient population and drive utilization growth.
Overall, PROCEPT's performance highlights its commitment to long-term value creation, market stability, and strategic growth initiatives in the medical robotics sector.

PROCEPT BioRobotics Corp reports strong revenue growth and strategic advancements

PROCEPT BioRobotics Corp delivered strong revenue growth in Q1 2024, driven by robust U.S. sales and improved gross margins. The company's strategic focus on profitability, customer relationships, and product safety positions it well for future success.
While facing challenges with net losses and high operating expenses, PROCEPT BioRobotics Corp has opportunities to drive growth through ASC procedures, international expansion, and clinical trials. Leveraging strategic partnerships and market-leading products will be key to overcoming challenges and seizing opportunities.
Overall, PROCEPT BioRobotics Corp's Q1 performance reflects a mix of strengths, challenges, and opportunities. By navigating financial hurdles, capitalizing on market trends, and maintaining a customer-centric approach, the company can drive sustainable growth and enhance its competitive position.

PROCEPT BioRobotics reports strong revenue growth but faces profitability challenges

PROCEPT BioRobotics delivered robust revenue growth and margin expansion in Q2 2024, driven by strong U.S. sales and operational efficiency. However, escalating operating expenses led to a net loss and negative adjusted EBITDA.
The company's strategic focus on leveraging fixed costs and sustaining revenue growth presents opportunities for long-term profitability and market expansion. Balancing cost control with revenue generation will be crucial for future success.
Despite challenges in achieving profitability, PROCEPT BioRobotics remains confident in its ability to drive margin expansion through increased revenues and operational efficiencies, positioning itself for sustained growth and financial improvement.

PROCEPT BioRobotics excels in Q3 with revenue surge and innovation

PROCEPT BioRobotics delivered strong revenue growth, margin improvement, and operational progress in Q3 2024, underpinned by market acceptance and innovation.
While facing challenges in managing expenses and achieving profitability, the company's solid financial position and growth outlook offer opportunities for future success.
By focusing on cost optimization, product differentiation, and strategic investments, PROCEPT can navigate challenges and leverage opportunities to drive sustained growth and value creation.
Overall, PROCEPT's performance reflects resilience and potential for continued expansion in the robotic medical systems market, supported by a strong financial foundation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. It manufactures and sells the AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating BPH. The firm's proprietary AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The company was founded by Nikolai Aljuri and Rodney C. Perkins in 2007 and is headquartered in San Jose, CA.

SAN JOSE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 35th Annual Piper Sandler Healthcare Conference in New York City. Management is scheduled to present on Wednesday, November 29 at 1:30 p.m. Eastern Time. A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the company's website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.

PROCEPT BioRobotics to Present at the 35ᵗʰ Annual Piper Sandler Healthcare Conference in New York City

The mean of analysts' price targets for PROCEPT BioRobotics Corporation (PRCT) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 25.54% Upside in PROCEPT BioRobotics Corporation (PRCT): Here's What You Should Know

PROCEPT BioRobotics Corporation (PRCT) Q3 2023 Earnings Call Transcript

SAN JOSE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2023.

PROCEPT BioRobotics® Reports Third Quarter 2023 Financial Results and Increases 2023 Revenue Guidance

PROCEPT BioRobotics Corporation (PRCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Broadcom

Ecovyst

Microchip Technology

NerdWallet

Semtech

Zebra Technologies

With the innovation sector moving at full speed, it's time for investors to consider the best tech stocks to buy now but not necessarily for the reason you might assume. Yes, the exchange-traded fund Technology Select Sector SPDR Fund (NYSEARCA: XLK ) has easily outperformed the benchmark SPDR S&P 500 ETF Trust (NYSEARCA: SPY ) over the past five years, 159% to 68%.

The 7 Best Tech Stocks To Buy Now: October 2023

SAN JOSE, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2023 after market close on Wednesday, November 1, 2023. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

PROCEPT BioRobotics to Report Third Quarter 2023 Financial Results on November 1, 2023

REDWOOD CITY, Calif., Aug. 22, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics”), a global leader in surgical robotics, announced today that it has successfully completed the first commercial Aquablation® therapy procedures in Japan. The procedures were carried out at two premier medical institutions, in association with the 100 patient post-market surveillance study. Completing the first commercial procedures in Japan represents another important milestone in PROCEPT BioRobotics' global expansion, highlighting the growing acceptance and recognition of Aquablation therapy as a pioneering solution for BPH patients.

PROCEPT BioRobotics® Announces First Commercial Aquablation Therapy Procedures in Japan

REDWOOD CITY, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2023 Wells Fargo Healthcare Conference in Boston. Management is scheduled to present on Thursday, September 7 at 3:00 p.m. Eastern Time. A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the company's website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.

PROCEPT BioRobotics to Present at the 2023 Wells Fargo Healthcare Conference in Boston

PRCT's aquablation therapy has shown strong growth, with revenues of $57.5mm in Q2 FY'23. The company's economic levers include new system placements, and growth from its installed base, with a record number of systems placed in Q2. Net-net, reiterate buy, eyeing a $40 price objective.

Procept BioRobotics: Adding Value Through Robust Unit Economics, Reiterate Buy

REDWOOD CITY, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the pricing of an upsized underwritten public offering of 4,422,169 shares of its common stock at a public offering price of $33.92 per share, before underwriting discounts and commissions, for aggregate gross proceeds of approximately $150 million. In addition, PROCEPT BioRobotics has granted the underwriters a 30-day option to purchase up to an additional 663,325 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the offering are to be sold by PROCEPT BioRobotics. The offering is expected to close on or about August 4, 2023, subject to customary closing conditions.

PROCEPT BioRobotics Corporation Announces Pricing of Upsized Offering of Common Stock

PROCEPT BioRobotics Corporation (PRCT) Q2 2023 Earnings Call Transcript

REDWOOD CITY, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2023.

PROCEPT BioRobotics® Reports Second Quarter 2023 Financial Results and Increases 2023 Revenue Guidance

REDWOOD CITY, Calif., July 11, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2023 before market open on Thursday, July 27, 2023. The Company's management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time.

PROCEPT BioRobotics to Report Second Quarter 2023 Financial Results on July 27, 2023

LOS ANGELES, CA / ACCESSWIRE / July 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PROCEPT BioRobotics Corporation ("Procept" or "the Company") (NASDAQ:PRCT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against PROCEPT BioRobotics Corporation and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

Procept had weak results on adding fewer than expected Aquabeam devices in Q1 of 2023, leading to a fall in the shares. Procept has strong potential in urology where its Aquablation technology has many potential indications. The company should rebound throughout the year on increased consumable usage and new deployments of its device through IDNs.

Procept BioRobotics: Adding For 2023 Rebound

LOS ANGELES, CA / ACECSSWIRE / May 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PROCEPT BioRobotics Corporation ("Procept" or "the Company") (NASDAQ:PRCT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against PROCEPT BioRobotics Corporation and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 24, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PROCEPT BioRobotics Corporation ("Procept" or "the Company") (NASDAQ:PRCT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against PROCEPT BioRobotics Corporation and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PROCEPT BioRobotics Corporation ("Procept" or "the Company") (NASDAQ:PRCT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against PROCEPT BioRobotics Corporation and Encourages Investors with Losses to Contact the Firm

LiveRamp Holdings Inc

Silicon Motion Technology

AbCellera Biologics

Hesai Group

Kymera Therapeutics

Schrodinger 

While the recent slow activity in the major indices clouds the narrative, you can still enjoy opportunities for growth stocks that could double your money. To be sure, you must be willing to accept some risks.

7 Growth Stocks That Could Double Your Money in 2023

Start Time: 08:00 January 1, 0000 8:56 AM ET PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q1 2023 Earnings Conference Call April 27, 2023, 08:00 AM ET Company Participants Reza Zadno - President and CEO Kevin Waters - EVP and CFO Matt Bacso - VP, IR and Business Operations Conference Call Participants Craig Bijou - Bank of America Joshua Jennings - Cowen Ryan Zimmerman - BTIG Chris Pasquale - Nephron Research Neil Chatterji - B. Riley Richard Newitter - Truist Nathan Treybeck - Wells Fargo Matthew Mishan - KeyBanc Operator Good morning, and welcome to the PROCEPT BioRobotics First Quarter 2023 Earnings Conference Call.

PROCEPT BioRobotics Corporation (PRCT) Q1 2023 Earnings Call Transcript

LOS ANGELES--(BUSINESS WIRE)---- $PRCT #PRCT--The Schall Law Firm Announces it is Investigating Claims Against PROCEPT BioRobotics Corporation and Encourages Investors to Contact the Firm.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against PROCEPT BioRobotics Corporation and Encourages Investors with Losses to Contact the Firm

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against PROCEPT BioRobotics Corporation and Encourages Investors with Losses to Contact the Firm

The company continues to grow revenue. It lost $28.5 million in the first quarter.

Why Shares of Procept Biorobotics Were Slumping Thursday

REDWOOD CITY, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2023.

News for PROCEPT BioRobotics Corp Stock (PRCT)